Evidence map›Paper›PMID 36750401›Full record

ArticleCancer reports (Hoboken, N.J.)2023

Concurrent immunotherapy and re-irradiation utilizing stereotactic body radiotherapy for recurrent high-grade gliomas.

Sean S Mahase, Michelle Roytman, Diana Roth O'Brien, Jana Ivanidze, Theodore H Schwartz, Susan C Pannullo, Rohan Ramakrishna, Rajiv S Magge, Nicholas Williams, Howard A Fine and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Sean S MahaseDepartment of Radiation Oncology, NewYork Presbyterian-Weill Cornell Medicine, New York, New York, USA.ORCID 0000-0003-3488-6981
Michelle RoytmanDepartment of Radiology, NewYork Presbyterian-Weill Cornell Medicine, New York, New York, USA.
Diana Roth O'BrienDepartment of Radiation Oncology, NewYork Presbyterian-Weill Cornell Medicine, New York, New York, USA.
Jana IvanidzeDepartment of Radiology, NewYork Presbyterian-Weill Cornell Medicine, New York, New York, USA.
Theodore H SchwartzDepartment of Neurosurgery, NewYork Presbyterian-Weill Cornell Medicine, New York, New York, USA.
Susan C PannulloDepartment of Neurosurgery, NewYork Presbyterian-Weill Cornell Medicine, New York, New York, USA.
Rohan RamakrishnaDepartment of Neurosurgery, NewYork Presbyterian-Weill Cornell Medicine, New York, New York, USA.
Rajiv S MaggeDepartment of Neurology, NewYork Presbyterian-Weill Cornell Medicine, New York, New York, USA.
Nicholas WilliamsDepartment of Healthcare Policy & Research, Division of Biostatistics and Epidemiology, Weill Cornell Medicine, New York, New York, USA.
Howard A FineDepartment of Neurology, NewYork Presbyterian-Weill Cornell Medicine, New York, New York, USA.
Gloria Chia-Yi ChiangDepartment of Radiology, NewYork Presbyterian-Weill Cornell Medicine, New York, New York, USA.
Jonathan P S KniselyDepartment of Radiation Oncology, NewYork Presbyterian-Weill Cornell Medicine, New York, New York, USA.
Cornell University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClinical trials evaluating immune checkpoint inhibition (ICI) in recurrent high-grade gliomas (rHGG) report 7%-20% 6-month progression-free survival (PFS), while re-irradiation demonstrates 28%-39% 6-month PFS.

aimsWe evaluate outcomes of patients treated with ICI and concurrent re-irradiation utilizing stereotactic body radiotherapy/fractionated stereotactic radiosurgery (SBRT) compared to ICI monotherapy. METHODS AND

resultsPatients ≥18-years-old with rHGG (WHO grade III and IV) receiving ICI + SBRT or ICI monotherapy between January 1, 2016 and January 1, 2019 were included. Adverse events, 6-month PFS and overall survival (OS) were assessed. Log-rank tests were used to evaluate PFS and OS. Histogram analyses of apparent diffusion coefficient maps and dynamic contrast-enhanced magnetic resonance perfusion metrics were performed. Twenty-one patients with rHGG (ICI + SBRT: 16; ICI: 5) were included. The ICI + SBRT and ICI groups received a mean 7.25 and 6.2 ICI cycles, respectively. There were five grade 1, one grade 2 and no grade 3-5 AEs in the ICI + SBRT group, and four grade 1 and no grade 2-5 AEs in the ICI group. Median PFS was 2.85 and 1 month for the ICI + SBRT and ICI groups; median OS was 7 and 6 months among ICI + SBRT and ICI groups, respectively. There were significant differences in pre and posttreatment tumor volume in the cohort (12.35 vs. 20.51; p = .03), but not between treatment groups.

conclusionsIn this heavily pretreated cohort, ICI with re-irradiation utilizing SBRT was well tolerated. Prospective studies are warranted to evaluate potential therapeutic benefits to re-irradiation with ICI + SBRT in rHGG.

Indexed as

GliomaRadiosurgeryRe-IrradiationAdolescentHumansImmunotherapyProgression-Free Survivalimmune checkpoint inhibitornivolumabpembrolizumabrecurrent high-grade gliomastereotactic body radiotherapy

Identifiers

PMID36750401
PMCPMC10363830
OpenAlexW4319335220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.